Canonic, a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) focused on the development of medical cannabis products, has started its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products.

The start of cannabis cultivation follows importing widely-genetically cannabis lines originating from different territories, the establishment of cannabis dedicated R&D facilities and the receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency.

Canonic’s scientific approach for developing cannabis products with unique genomic profiles is based on decoding the cannabis plant’s genome to overcome the current market challenges associated with these products. The company employs Evogene’s technology, the CPB platform, plant genomics, Big Data, and artificial intelligence.

The company plans to use the genomic data of the new varieties imported to expand its genomic database and to be integrated in the CPB’s computational platforms in order to accelerate development efforts.

“We are excited to kick-off our cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of state-of-the-art medical cannabis products. This achievement is in line with our 2019 milestones, outlined earlier this year, and will allow Canonic to accelerate its product development in the coming year with a focus on achieving unique cannabis varieties addressing specific medical needs,” Canonic CEO Arnon Heyman stated.